View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
HHS/FDA | RIN: 0910-AG87 | Publication ID: Fall 2014 |
Title: Blood Initiative--Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use | |
Abstract:
FDA is amending the regulations applicable to blood and blood components, including Source Plasma, to make the donor eligibility and testing requirements, more consistent with current practices in the blood industry to more closely align the regulations with current FDA recommendations, and to provide flexibility to accommodate advancing technology. These actions are intended to help ensure the continued safety of the Nation's blood supply and to help protect donor health. |
|
Agency: Department of Health and Human Services(HHS) | Priority: Other Significant |
RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Final Rule Stage |
Major: Undetermined | Unfunded Mandates: No |
CFR Citation: 21 CFR 606 21 CFR 610 21 CFR 630 21 CFR 640 21 CFR 660 21 CFR 820 | |
Legal Authority: 21 USC 321 21 USC 331 21 USC 351 to 353 21 USC 355 21 USC 360 21 USC 360c to 360e 21 USC 360h to 360j 21 USC 360l 21 USC 371 21 USC 372 21 USC 374 21 USC 381 21 USC 383 42 USC 216 42 USC 262 42 USC 263 42 USC 263a 42 USC 264 |
Legal Deadline:
None |
||||||||||||||||||
Timetable:
|
Regulatory Flexibility Analysis Required: No | Government Levels Affected: None |
Small Entities Affected: Businesses | Federalism: No |
Included in the Regulatory Plan: No | |
RIN Data Printed in the FR: No | |
Agency Contact: Valerie A. Butler Team Leader Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research, 10903 New Hampshire Avenue, Building 71, Silver Spring, MD 20903-0002 Phone:240 402-7911 Fax:301 595-1310 |